ArticleFrontiers in oncology2025
Correlation of heat shock protein 1 expression with progression and prognosis of non-small cell lung cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Heat shock protein family H member 1 HSPH1 expression correlates with progression and prognosis of hepatocellular carcinoma.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: To investigate the expression and clinical significance of heat shock protein H1 (HSPH1) in non-small cell lung cancer (NSCLC). To provide new and reliable biomarkers for the treatment of NSCLC. Main methods: Various public databases were used to analyse the molecular characteristics, disease relevance and expression differences of HSPH1 and to investigate the correlation between HSPH1 expression and prognosis in NSCLC patients. MsigDB and Molecular signatures database were used for enrichment analysis. The HSPH1 protein interaction network was constructed using the STRING database. In addition, immune infiltration analysis was performed. Subsequently, the expression levels of HSPH1 in Lung cancer cell lines, human NSCLC tissues and normal tissues were determined using various experiments. Finally, a retrospective analysis was performed to determine whether the expression level of HSPH1 was associated with the clinical characteristics and prognosis of NSCLC patients. Results: The high expression of HSPH1 in NSCLC was significantly correlated with the clinical characteristics and poor prognosis of patients, and it may affect the progression of NSCLC by forming a regulatory network with molecules such as HSPA8, BAG2, etc., and its mechanism may involve the regulation of the P53 signalling pathway, G2M_CHECKPOINT and mTORC1_SGNALING. Experiments confirmed that HSPH1 was also highly expressed in NSCLC tissues and cells. Conclusion: HSPH1 can be used as a potential diagnostic and prognostic marker for NSCLC, and its involvement in NSCLC progression and immune regulation may be one of its therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.